Overview

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
AB-10-8005 is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with HBeAg-negative CHB treated with nucleos (t) ide analogues.
Phase:
PHASE2
Details
Lead Sponsor:
Ausper Biopharma Co., Ltd.